The U.S. Food and Drug Administration has granted approval for Kisunla (donanemab-azbt) injection, marking a significant development in Alzheimer’s disease treatment.

Highlights

• The FDA has approved Kisunla (donanemab-azbt) injection for treating Alzheimer’s disease in adults with mild cognitive impairment or mild dementia. Kisunla is administered as an intravenous infusion every four weeks.
• The efficacy of Kisunla was demonstrated in a clinical trial involving 1736 patients with confirmed amyloid pathology. Results showed significant reduction in clinical decline on various scales, including the Integrated Alzheimer's Disease Rating Scale (iADRS) and the Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB).
• The study population had a mean age of 73 years, with the majority being White (91%) and female (57%).

About Alzheimer’s Disease

Alzheimer’s disease is an irreversible, progressive brain disorder affecting more than 6.5 million Americans. It leads to memory loss, cognitive decline, and affects daily activities due to changes in the brain such as amyloid beta plaques and tau tangles.

Efficacy Study

The efficacy of Kisunla was evaluated in a double-blind, placebo-controlled study (NCT04437511) over 72 weeks. Patients treated with Kisunla showed statistically significant improvements in cognitive and functional decline compared to placebo.